Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01108913 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: Bimosiamose
DRUG: Placebo

Sponsor

Revotar Biopharmaceuticals AG